FilingReader Intelligence
Ascentage Pharma's lisaftoclax approved in China for CLL/SLL treatment
July 10, 2025 at 09:11 AM UTC•By FilingReader AI
Ascentage Pharma Group International announced that its proprietary novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), has been approved by China’s National Medical Products Administration (NMPA).
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:6855•Hong Kong Exchange
News Alerts
Get instant email alerts when Ascentage Pharma Group Intl publishes news
Free account required • Unsubscribe anytime